Skip to main content
. 2023 Oct 27;24(21):15658. doi: 10.3390/ijms242115658

Figure 1.

Figure 1

UBE2C and PLK1 are significantly upregulated in pan-cancer tissues and cells. The expression levels of UBE2C (A) and PLK1 (C) in normal tissues and tumor samples. Gene expression variance between different groups was determined using a Wilcoxon test. The expression levels of UBE2C (B) and PLK1 (D) in pathological stages. One-way ANOVA analysis with Bonferroni post hoc test. Kaplane–Meier estimates of overall survival (OS) are shown according to the expression level of UBE2C (E) and PLK1 (F) with the 95% confidence interval shown as dashed lines. Note that the patients with low groups (in blue) display better survival than those with high groups (in red). ACC, Adrenocortical carcinoma; BRCA, Breast invasive carcinoma; KICH, Kidney chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LGG, Brain lower-grade glioma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; MESO, Mesothelioma; PAAD, Pancreatic adenocarcinoma; SKCM, Skin cutaneous melanoma; UVM, Uveal melanoma ns—No significance; *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.0001.